TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03656432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP paste
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP paste
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP paste
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
Study: NCT02040818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline, N-acetylcysteine, heparin combination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: guide-wire exchange
Study: NCT01794819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-reactive protein test
Description: Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
Study: NCT02648724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
Study: NCT01218269

Intervention type: DEVICE
Group type: OTHER
Intervention: nitinol u-clip
Description: The U-clip is comprised of nitinol, an alloy of nickel and titanium.
Study: NCT02648724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
Study: NCT00831025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with modified extract of Olea europaea pollen
Description: Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
Study: NCT02648724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
Study: NCT02556593

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Daily IMRT at 45 Gy in 15 fractions to brain metastases
Study: NCT02878382

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional MAL-PDT
Description: Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
Study: NCT02556593

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: 3DCRT at 30 Gy in 10 fractions to whole brain
Study: NCT02878382

Intervention type: OTHER
Group type: OTHER
Intervention: Calcipotriol assisted MAL-PDT
Description: Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
Study: NCT01710566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
Study: NCT03402841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg twice daily - oral
Study: NCT02993263

Intervention type: DEVICE
Group type: OTHER
Intervention: VectraplexECG System with CEB®
Description: The device will be used after noncardiac surgery
Study: NCT00365807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Fit
Description: 12-week group intervention for children with obesity and their parents/caregivers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Family Intervention (Primarily education)
Description: 3 hours of contact with registered dietician for education and nutritional counseling.
Study: NCT02556593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150mg daily
Study: NCT02175771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening.
Study: NCT01634152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 actuations once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low dose mcg
Description: 2 actuations once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high dose
Description: 2 actuations once daily in the evening
Study: NCT03615885

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Capsules
Description: Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Juice
Description: 100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml).
Study: NCT03191006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEI BIN insoles
Description: insoles
Study: NCT00738699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study: NCT03179722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional data collection: questionnaires
Description: Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management
Study: NCT03789786

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and Motion Analysis
Description: Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and Motion Analysis
Description: Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Gross Motor Function Measure (GMFM)
Description: Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping

Intervention type: DIAGNOSTIC_TEST
Intervention: Gross Motor Function Measure (GMFM)
Description: Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
Study: NCT04052165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glaucoma Implant
Study: NCT03789786

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
Study: NCT03185780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas.
Study: NCT03411278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Oscillation (DO)
Description: DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order.
Study: NCT03195426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal nerves blocks group
Description: * ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic function assessment
Description: Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure.
Study: NCT03692013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
Study: NCT03854253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long introducer sheath
Description: The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
Study: NCT03418857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12
Description: During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt smoothie
Description: During the one month control period, the participants will consume one yogurt smoothie daily.
Study: NCT02011919

Intervention type: DEVICE
Group type: OTHER
Intervention: Echopulse
Description: HIFU Under ultrasound guidance
Study: NCT03854253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short introducer sheath
Description: The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
Study: NCT00711126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 2.5mcg IV
Study: NCT02112084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized DPM
Description: The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
Study: NCT00413114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070MS)
Study: NCT00711126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 5mcg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 10mcg IV
Study: NCT01152437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
Study: NCT00711126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 100mcg inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 20mcg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 500mcg oral
Study: NCT04030767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox Injectable Product
Description: Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Study: NCT01562925

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red wine
Description: Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Study: NCT02426593

Intervention type: DEVICE
Intervention: IMED-4
Description: Non-invasive novel lung hydration status sensor.
Study: NCT03364673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness Tracker
Description: Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Incentive (Way to Health)
Description: The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
Study: NCT01562925

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White wine
Description: White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beer
Description: Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
Study: NCT05089097

Intervention type: OTHER
Intervention: evaluation of delirium with CAM-ICU Score
Description: the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject

Intervention type: OTHER
Intervention: evaluation of delirium with CAM-ICU Score
Description: the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
Study: NCT01234116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate
Description: Each health care worker will receive one of the Treatment Arms for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate
Description: Each health care worker will receive one of the Treatment Arms for 28 days.
Study: NCT02377726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alkoholhjälpen counselor support
Description: Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eChange Alkoholhjälpen
Description: An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eChange Alkoholhjälpen
Description: An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alkoholhjälpen
Description: A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
Study: NCT03473522

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
Study: NCT01491308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cells transfusion
Description: This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cells transfusion
Description: This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.